These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33340905)

  • 41. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
    Veitch Z; Zer A; Loong H; Salah S; Masood M; Gupta A; Bradbury PA; Hogg D; Wong A; Kandel R; Charames GS; Abdul Razak AR
    Sci Rep; 2019 May; 9(1):7390. PubMed ID: 31089155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
    Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
    Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
    Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
    Teshima Y; Nomura S; Fukasawa N
    Jpn J Clin Oncol; 2021 Apr; 51(4):612-621. PubMed ID: 33283234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study.
    Noujaim J; Gupta AA; Holloway CL; Saleh R; Srikanthan A; Lemieux C; Soroka HP; Tibout P; Turcotte R; Feng X; Abdul Razak AR; Costa P
    Eur J Cancer; 2024 Jul; 205():114119. PubMed ID: 38759389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
    Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
    Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
    J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
    Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
    J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
    Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
    J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Sideras K; Morris JC; McIver B; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Goh BC; Tang H; Ivy SP; Erlichman C; ; ;
    Lancet Oncol; 2010 Oct; 11(10):962-72. PubMed ID: 20851682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
    Queiroz Muniz D; Ratto B; Yang H; Zhao J; Jenkins M; Signorovitch J; Dezzani L; Salman P; Lema Medina M; Lopera D; Lerzo G; Del Castillo C; Chacon M; Martin A; Campos-Gomez S
    Adv Ther; 2019 Dec; 36(12):3446-3457. PubMed ID: 31630333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.
    Menegaz BA; Cuglievan B; Benson J; Camacho P; Lamhamedi-Cherradi SE; Leung CH; Warneke CL; Huh W; Subbiah V; Benjamin RS; Patel S; Daw N; Hayes-Jordan A; Ludwig JA
    Oncologist; 2018 Mar; 23(3):360-366. PubMed ID: 29212731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
    Mir O; Touati N; Lia M; Litière S; Le Cesne A; Sleijfer S; Blay JY; Leahy M; Young R; Mathijssen RHJ; Van Erp NP; Gelderblom H; Van der Graaf WT; Gronchi A
    Clin Cancer Res; 2019 Mar; 25(5):1479-1485. PubMed ID: 30765389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
    Wilding CP; Elms ML; Judson I; Tan AC; Jones RL; Huang PH
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):971-991. PubMed ID: 31665941
    [No Abstract]   [Full Text] [Related]  

  • 59. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Besse B; Mazières J; Ribassin-Majed L; Barlesi F; Bennouna J; Gervais R; Moreau L; Berard H; Debieuvre D; Molinier O; Moro-Sibilot D; Souquet PJ; Jacquot S; Petit L; Lena H; Pignon JP; Lacas B; Morin F; Milleron B; Zalcman G; Soria JC;
    Ann Oncol; 2017 May; 28(5):1078-1083. PubMed ID: 28327934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
    Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
    Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.